NUFORMIX PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.19 GBX | -5.00% |
|
-7.32% | -41.54% |
| Mar. 01 | Nuformix announces subscription to raise GBP150,000 | AN |
| Jan. 15 | Nuformix plc Reports Earnings Results for the Eighteen Months Ended September 30, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products that are differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001 is pursuing licensing opportunities. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.
Sector
Pharmaceuticals
Calendar
2024-07-24
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -41.54% | 1.94M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- LVRT Stock
- News Nuformix plc
- Earnings Flash (NFX.L) NUFORMIX Reports FY23 Loss GBX-0.12
